Literature DB >> 24552354

Melatonin and tadalafil treatment improves erectile dysfunction after spinal cord injury in rats.

Hasan Hüseyin Tavukçu1, Tarik Emre Sener, Ilker Tinay, Cem Akbal, Mehmet Erşahin, Ozge Cevik, Selin Cadirci, Russel J Reiter, Göksel Sener.   

Abstract

Oxidative stress plays an important role both in spinal cord injury (SCI) and erectile dysfunction (ED). The present study investigated the effects of melatonin and tadalafil treatment alone or in combination on SCI-induced ED. Male Wistar albino rats (n = 40) were divided into five groups: sham-operated control and SCI-injured rats given either vehicle, melatonin (10 mg/kg, i.p.), tadalafil (10 mg/kg, p.o.) or a combination of melatonin and tadalafil. Spinal cord injury was induced using a standard weight-drop method. On Day 7 after SCI, intracavernosal pressure (ICP) was measured and all rats were decapitated. Cavernosal tissues were obtained to examine caspase 3, nitric oxide synthase (NOS), myeloperoxidase (MPO) and superoxide dismutase (SOD) activities, as well as cGMP, nerve growth factor (NGF), malondialdehyde (MDA) and glutathione (GSH) levels. Spinal cord injury caused oxidative damage, as evidenced by increases in MDA and cGMP levels. In addition, MPO and caspase 3 activites were increased after SCI, whereas GSH and NGF levels and SOD activity were reduced. Melatonin effectively reversed these oxidative changes. Furthermore, in rats treated with both melatonin and tadalafil, the recoveries were more pronounced than in rats given either melatonin or tadalafil alone. The ICP/mean arterial pressure value in vehicle-treated SCI rats was significantly higher than in the control group, whereas in the tadalafil- and tadalafil + melatonin-treated groups have returned this value had returned to control levels. As an individual treatment, and especially when combined with tadalafil, a well-known agent in the treatment of ED, melatonin prevented SCI-induced oxidative damage to cavernosal tissues and restored ED, most likely due to its anti-oxidant effects.
© 2014 Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  apoptosis; erectile dysfunction; melatonin; spinal cord injury; tadalafil

Mesh:

Substances:

Year:  2014        PMID: 24552354     DOI: 10.1111/1440-1681.12216

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  6 in total

1.  Wogonin prevents rat dorsal root ganglion neurons death via inhibiting tunicamycin-induced ER stress in vitro.

Authors:  Shujuan Xu; Xin Zhao; Quanlai Zhao; Quan Zheng; Zhen Fang; Xiaoming Yang; Hong Wang; Ping Liu; Hongguang Xu
Journal:  Cell Mol Neurobiol       Date:  2014-11-09       Impact factor: 5.046

Review 2.  Biomaterial strategies for limiting the impact of secondary events following spinal cord injury.

Authors:  Trevor R Ham; Nic D Leipzig
Journal:  Biomed Mater       Date:  2018-02-08       Impact factor: 3.715

3.  Penile erectile dysfunction after brachial plexus root avulsion injury in rats.

Authors:  Guo Fu; Bengang Qin; Li Jiang; Xijun Huang; Qinsen Lu; Dechun Zhang; Xiaolin Liu; Jiakai Zhu; Jianwen Zheng; Xuejia Li; Liqiang Gu
Journal:  Neural Regen Res       Date:  2014-10-15       Impact factor: 5.135

Review 4.  Melatonin for the treatment of spinal cord injury.

Authors:  Yan Zhang; Wen-Xiu Zhang; Yan-Jun Zhang; Ya-Dong Liu; Zong-Jian Liu; Qi-Chao Wu; Yun Guan; Xue-Ming Chen
Journal:  Neural Regen Res       Date:  2018-10       Impact factor: 5.135

Review 5.  Evidence for the Benefits of Melatonin in Cardiovascular Disease.

Authors:  Mohammad Tobeiha; Ameneh Jafari; Sara Fadaei; Seyed Mohammad Ali Mirazimi; Fatemeh Dashti; Atefeh Amiri; Haroon Khan; Zatollah Asemi; Russel J Reiter; Michael R Hamblin; Hamed Mirzaei
Journal:  Front Cardiovasc Med       Date:  2022-06-20

6.  Low serum melatonin levels are associated with erectile dysfunction.

Authors:  Aliseydi Bozkurt; Mehmet Karabakan; Binhan Kagan Aktas; Murat Gunay; Ercüment Keskin; Erkan Hirik
Journal:  Int Braz J Urol       Date:  2018 Jul-Aug       Impact factor: 1.541

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.